AM Best Requests Comments on Proposed Revisions to ‘Life Settlement Securitization’ Criteria

AM Best is seeking industry comments through Oct. 9, 2026, on a draft update to its Life Settlement Securitization criteria. The principal proposed change is adoption of the 2015 Valuation Basic Tables for mortality rates, alongside other methodology updates. The consultation could affect ratings analysis for life-settlement securitizations but is not an immediate market-moving event.

Analysis

This is primarily a private-credit and structured-finance surveillance item rather than an actionable public-equity catalyst. Updating mortality assumptions can alter expected cash-flow timing and reserve requirements for life-settlement securitizations, with the greatest effect on subordinated tranches and managers holding residual interests; senior notes should be relatively insulated unless revised assumptions materially lengthen insured lives. The consultation itself does not change ratings, capital charges, or transaction economics, so any near-term market impact should be negligible.

The relevant 1-3 month watch item is whether industry feedback identifies a systematic mismatch between the proposed tables and actual longevity experience in the life-settlement population. A methodology that implies longer durations would lower present values, increase financing needs for premium payments, and pressure equity returns for originators and fund sponsors; shorter implied durations would have the reverse effect. Because these assets are privately held and thinly traded, valuation marks may lag any underlying economic change until financing renewals, ratings actions, or fund NAV reports.

Contrarian point: headline regulatory-methodology updates often prompt excessive concern about broad life-insurer credit. The exposure is concentrated in specialty settlement vehicles, not conventional life carriers' core liability books. A trade is not warranted without evidence of named issuers, outstanding securitization balances, tranche-level sensitivity, or a final methodology that drives rating migration.

Key Decisions for Investors

• No directional public-equity or liquid-credit trade at this stage; maintain as a low-priority regulatory watch item through the comment deadline and subsequent final methodology publication.
• For private-credit portfolios, request manager-level exposure reports for life-settlement ABS, including weighted-average life sensitivity to mortality-table changes, premium-reserve coverage, refinancing dates, and residual-interest NAV exposure within the next 30 days.
• Set an alert for any AM Best rating actions or negative outlooks on named life-settlement issuers following finalization; downgrade activity, rather than the consultation, would be the actionable catalyst for reducing subordinated-tranche exposure.
• Thesis falsifier: evidence that revised tables produce less than a modest change in weighted-average life and do not trigger reserve, collateral, or rating changes would confirm that the update is economically immaterial.